Short answer
Prime Medicine, Inc. (PRME) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $125.0 million base equity offering: 35,714,286 shares priced at $3.50 each.
Prime Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $125.0 million base equity offering: 35,714,286 shares priced at $3.50 each
- Additional 5,357,142-share underwriter option, potentially increasing gross proceeds
- Approximately $134.7 million expected net proceeds if the option is fully exercised
- Funding targeted primarily at Wilson disease, alpha-1 antitrypsin deficiency and other R&D programs
- Material shareholder dilution, with closing expected around November 12, 2026 subject to customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Prime Medicine, Inc. 8-K filings
Get the next PRME 8-K as it lands
Follow PRME for push alerts, or ask the research agent what this filing means.